Nordic Therapeutic Alliance (NTA)
| Reference number | |
| Coordinator | Cytiva Testa Center AB |
| Funding from Vinnova | SEK 1 495 853 |
| Project duration | October 2025 - March 2026 |
| Status | Ongoing |
| Venture | Cluster of Excellence for Cutting-Edge Technologies - calls for proposals |
| Call | Visions for world-leading research and innovation in strategic technology areas |
Important results from the project
NTA has laid the foundation and created momentum for an internationally competitive excellence cluster excellence with vision to strengthen Sweden´s and the Nordic region´s position in innovative biological precision therapies and ATMPs by mobilizing a committed consortium of actors from industry, academia, healthcare, public sector and innovation support around a common, anchored vision and implementation plan where research excellence, technology development and industrial capacity interact.
Expected long term effects
The project is expected to strengthen Sweden´s and the Nordic region´s capabilities in research, development and production of innovative biological precision therapies and ATMPs through lasting collaboration between academia, industry, healthcare and innovation actors that creates conditions for shorter lead times, increased innovation, strengthened international attractiveness, increased preparedness and resilience and allows advanced therapies to reach patients in a cost-effective manner.
Approach and implementation
The project was implemented according to plan and began with a two-day kick-off with workshops that brought together over 50 participants and laid the foundation for continued work in thematic groups (vision and scenarios, business model, governance, organization, KPIs etc) with regular report-outs that was open to the public and ended with a joint consolidation meeting. A team of 11 people from Testa Center, UU, ORU, STUNS and KI has been responsible for project management and facilitation.